FI87075C - Foerfarande foer framstaellning av terapeutiskt aktiva 4,5-dihydro- och 3,4,5,6-tetrahydro-2h-oxazolocykloalkylpyridinderivat - Google Patents
Foerfarande foer framstaellning av terapeutiskt aktiva 4,5-dihydro- och 3,4,5,6-tetrahydro-2h-oxazolocykloalkylpyridinderivat Download PDFInfo
- Publication number
- FI87075C FI87075C FI882504A FI882504A FI87075C FI 87075 C FI87075 C FI 87075C FI 882504 A FI882504 A FI 882504A FI 882504 A FI882504 A FI 882504A FI 87075 C FI87075 C FI 87075C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- derivatives
- tetrahydro
- dihydro
- mixture
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 230000004913 activation Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000000047 product Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000007859 condensation product Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 241000277284 Salvelinus fontinalis Species 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 abstract description 11
- 230000002107 myocardial effect Effects 0.000 abstract description 4
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical class OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 abstract description 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000000496 cardiotonic agent Substances 0.000 abstract 1
- 230000003177 cardiotonic effect Effects 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 14
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000000747 cardiac effect Effects 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- -1 cyclic oxime Chemical class 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000208011 Digitalis Species 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 150000001204 N-oxides Chemical class 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000003997 cyclic ketones Chemical class 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 3
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 2
- XGYCAOWIWCNPHM-UHFFFAOYSA-N 2-oxido-1H-cyclohepta[c]pyridin-2-ium Chemical compound C1[N+](=CC=C2C1=CC=CC=C2)[O-] XGYCAOWIWCNPHM-UHFFFAOYSA-N 0.000 description 2
- HJGKGMOBSNNJQZ-UHFFFAOYSA-N 4,5-dihydro-3h-[1,3]oxazolo[5,4-f]isoquinolin-2-one Chemical compound C1CC2=CN=CC=C2C2=C1NC(=O)O2 HJGKGMOBSNNJQZ-UHFFFAOYSA-N 0.000 description 2
- RXQZQYFJZQINDS-UHFFFAOYSA-N 6-amino-6h-isoquinolin-5-one Chemical compound N1=CC=C2C(=O)C(N)C=CC2=C1 RXQZQYFJZQINDS-UHFFFAOYSA-N 0.000 description 2
- PXWTWRQYCADVIG-UHFFFAOYSA-N 6-aminocyclohepta[c]pyridin-5-one Chemical compound O=C1C(N)=CC=CC2=CN=CC=C21 PXWTWRQYCADVIG-UHFFFAOYSA-N 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OSCUZCXGDSWWFL-UHFFFAOYSA-N N-(6H-isoquinolin-5-ylidene)hydroxylamine Chemical compound N1=CC=C2C(=NO)CC=CC2=C1 OSCUZCXGDSWWFL-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- PBXQUYBUHZMILR-UHFFFAOYSA-N cyclohepta[c]pyridin-5-one Chemical compound O=C1C=CC=CC2=CN=CC=C12 PBXQUYBUHZMILR-UHFFFAOYSA-N 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical class O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- TXSNVQYKSSLTDI-UHFFFAOYSA-N 2h-cyclohepta[c]pyridin-5-ol Chemical compound C1=CC=CC(O)=C2C=CNC=C21 TXSNVQYKSSLTDI-UHFFFAOYSA-N 0.000 description 1
- OKJDEBURSPYOAV-UHFFFAOYSA-N 2h-cyclohepta[c]pyridin-5-yl acetate Chemical compound C1=CC=CC(OC(=O)C)=C2C=CNC=C21 OKJDEBURSPYOAV-UHFFFAOYSA-N 0.000 description 1
- CDZCREIHDRCTHZ-UHFFFAOYSA-N 2h-cyclohepta[c]pyridine Chemical compound C1=CC=CC2=CNC=CC2=C1 CDZCREIHDRCTHZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZDQCLDBVVQUHDH-UHFFFAOYSA-N 6h-isoquinolin-5-one Chemical compound N1=CC=C2C(=O)CC=CC2=C1 ZDQCLDBVVQUHDH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- IFHARJWYMPCYJX-UHFFFAOYSA-N C(C)(=O)OC=1NC=CC=2C1C=CC=CC2 Chemical compound C(C)(=O)OC=1NC=CC=2C1C=CC=CC2 IFHARJWYMPCYJX-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OREHUUWZZYQZNA-UHFFFAOYSA-N N-cyclohepta[c]pyridin-5-ylidenehydroxylamine Chemical compound ON=C1C=CC=CC2=CN=CC=C12 OREHUUWZZYQZNA-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000021264 digitalis poisoning Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- VIJMMQUAJQEELS-UHFFFAOYSA-N n,n-bis(ethenyl)ethenamine Chemical compound C=CN(C=C)C=C VIJMMQUAJQEELS-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Laminated Bodies (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5548587A | 1987-05-29 | 1987-05-29 | |
| US5548587 | 1987-05-29 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI882504A0 FI882504A0 (fi) | 1988-05-27 |
| FI882504L FI882504L (fi) | 1988-11-30 |
| FI87075B FI87075B (fi) | 1992-08-14 |
| FI87075C true FI87075C (fi) | 1992-11-25 |
Family
ID=21998160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI882504A FI87075C (fi) | 1987-05-29 | 1988-05-27 | Foerfarande foer framstaellning av terapeutiskt aktiva 4,5-dihydro- och 3,4,5,6-tetrahydro-2h-oxazolocykloalkylpyridinderivat |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0293777B1 (https=) |
| JP (1) | JP2640671B2 (https=) |
| KR (1) | KR880013942A (https=) |
| CN (1) | CN1019116B (https=) |
| AT (1) | ATE83777T1 (https=) |
| AU (1) | AU600134B2 (https=) |
| CA (1) | CA1329601C (https=) |
| DE (1) | DE3876859T2 (https=) |
| DK (1) | DK290488A (https=) |
| ES (1) | ES2053621T3 (https=) |
| FI (1) | FI87075C (https=) |
| GR (1) | GR3007091T3 (https=) |
| HU (1) | HU198497B (https=) |
| IL (1) | IL86517A (https=) |
| NO (1) | NO882340L (https=) |
| NZ (1) | NZ224745A (https=) |
| PH (1) | PH25792A (https=) |
| PT (1) | PT87598B (https=) |
| ZA (1) | ZA883659B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4762843A (en) * | 1986-09-15 | 1988-08-09 | Warner-Lambert Company | Hetero [f] fused carbocyclic pyridines as dopaminergic agents |
| MY106964A (en) * | 1988-04-28 | 1995-08-30 | Schering Corp | Fused polycyclic compounds, compositions, methods of manufacture, and their use as paf antagonists, antihistamines and/or antiinflammatory agents. |
| CN102696363A (zh) * | 2012-06-27 | 2012-10-03 | 莱恩农业装备有限公司 | 一种防卡刀碎草机构 |
| CN102696364A (zh) * | 2012-06-28 | 2012-10-03 | 莱恩农业装备有限公司 | 一种卡刀自动调整碎草机构 |
-
1988
- 1988-05-23 NZ NZ224745A patent/NZ224745A/xx unknown
- 1988-05-23 ZA ZA883659A patent/ZA883659B/xx unknown
- 1988-05-25 CA CA000567708A patent/CA1329601C/en not_active Expired - Fee Related
- 1988-05-25 AU AU16624/88A patent/AU600134B2/en not_active Ceased
- 1988-05-26 IL IL86517A patent/IL86517A/xx unknown
- 1988-05-27 DE DE8888108496T patent/DE3876859T2/de not_active Expired - Fee Related
- 1988-05-27 ES ES88108496T patent/ES2053621T3/es not_active Expired - Lifetime
- 1988-05-27 DK DK290488A patent/DK290488A/da not_active Application Discontinuation
- 1988-05-27 JP JP63130056A patent/JP2640671B2/ja not_active Expired - Lifetime
- 1988-05-27 AT AT88108496T patent/ATE83777T1/de active
- 1988-05-27 HU HU882714A patent/HU198497B/hu not_active IP Right Cessation
- 1988-05-27 EP EP88108496A patent/EP0293777B1/en not_active Expired - Lifetime
- 1988-05-27 PT PT87598A patent/PT87598B/pt not_active IP Right Cessation
- 1988-05-27 NO NO882340A patent/NO882340L/no unknown
- 1988-05-27 FI FI882504A patent/FI87075C/fi not_active IP Right Cessation
- 1988-05-28 KR KR1019880006306A patent/KR880013942A/ko not_active Withdrawn
- 1988-05-30 CN CN88103236A patent/CN1019116B/zh not_active Expired
- 1988-05-30 PH PH36992A patent/PH25792A/en unknown
-
1993
- 1993-02-17 GR GR930400324T patent/GR3007091T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI882504A0 (fi) | 1988-05-27 |
| DE3876859T2 (de) | 1993-04-29 |
| FI87075B (fi) | 1992-08-14 |
| ATE83777T1 (de) | 1993-01-15 |
| PH25792A (en) | 1991-11-05 |
| PT87598B (pt) | 1995-03-01 |
| AU600134B2 (en) | 1990-08-02 |
| ZA883659B (en) | 1989-01-25 |
| HU198497B (en) | 1989-10-30 |
| IL86517A (en) | 1991-11-21 |
| EP0293777A1 (en) | 1988-12-07 |
| JP2640671B2 (ja) | 1997-08-13 |
| AU1662488A (en) | 1988-12-01 |
| ES2053621T3 (es) | 1994-08-01 |
| NO882340D0 (no) | 1988-05-27 |
| NO882340L (no) | 1988-11-30 |
| CA1329601C (en) | 1994-05-17 |
| CN1019116B (zh) | 1992-11-18 |
| DK290488A (da) | 1988-11-30 |
| GR3007091T3 (https=) | 1993-07-30 |
| PT87598A (pt) | 1989-05-31 |
| HUT47585A (en) | 1989-03-28 |
| DK290488D0 (da) | 1988-05-27 |
| NZ224745A (en) | 1990-09-26 |
| EP0293777B1 (en) | 1992-12-23 |
| CN88103236A (zh) | 1988-12-21 |
| DE3876859D1 (de) | 1993-02-04 |
| IL86517A0 (en) | 1988-11-15 |
| FI882504L (fi) | 1988-11-30 |
| KR880013942A (ko) | 1988-12-22 |
| JPS6419080A (en) | 1989-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS247073B2 (en) | Production method of 2-substituted 4-amino-6,7-dimethoxyghinolins | |
| CH660191A5 (fr) | Derives de la furo-(3,4-c)-pyridine, leur preparation et compositions therapeutiques contenant ces derives. | |
| SU1503681A3 (ru) | Способ получени производных 1-(гидроксистирил)-5Н-2,3-бензодиазепина | |
| FI87075C (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 4,5-dihydro- och 3,4,5,6-tetrahydro-2h-oxazolocykloalkylpyridinderivat | |
| CA1169081A (en) | 8-aminoalkyl-4-alkylisopsoralens | |
| JPS584715B2 (ja) | 新規なアリ−ルトリフルオロエチルアミン | |
| FI88034C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3,4,5-tetrahydro-2h-imidazo/4,5-f/isokinolin-2-on | |
| MC1395A1 (fr) | Derives de la pyrimidine | |
| US4291034A (en) | 7-Chloro-3-substituted aryl-3,4-dihydro-1,9(2H,10H) and 10 hydroxy acridinedioneimines having antimalarial activity | |
| US4992457A (en) | Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease | |
| CZ278281B6 (en) | ENOL ETHER OF 1,1-DIOXIDE OF 6-CHLORO-4-HYDROXY-2-METHYL-N- (2-PYRIDYL-2H-THIENO(2,3-c)-1,2-THIAZINECARBOXYLIC ACID AMIDE, PROCESS OF ITS PREPARATION AND ITS USE | |
| US4803210A (en) | Cardiotonic tricyclic oxazolones | |
| FI81802C (fi) | Foerfarande foer framstaellning av terapeutiskt verksamt 2-(3-metoxi-5-metyltio- eller 5-metylsulfinyl-2-tienyl-1h-imidazo(4,5-c)pyridin. | |
| RU2068415C1 (ru) | 5,7-диокси-2-метил-8-/4-(3-окси-1-(1-пропил)пиперидинил/-4н-1-бензопиран-4-он или его стереоизомеры или фармакологически приемлемые кислотно-аддитивные соли и способ их получения | |
| FI87775B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbar 5-(2-naftyl)-2,4-dimetyl-3h-1,2,4-triazol-3-tion | |
| US4061772A (en) | Derivatives of the 1,2-diarylethylene and pharmaceutical compositions thereof | |
| US4001431A (en) | Derivatives of the 1,2-diarylethylene- and pharmaceutical compositions thereof | |
| FI57944B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-amino-6-metyl-4-nitrofenyl-4h-pyraner | |
| JPH0526777B2 (https=) | ||
| JPH03112964A (ja) | 環状アミノ置換スチレン誘導体および前記化合物を有効成分とする強心剤 | |
| JPH0211568A (ja) | ２―ピリジル酢酸誘導体 | |
| CH628350A5 (en) | Thiazole derivatives and anthelmintic composition containing them | |
| JPS5813543B2 (ja) | ビンカミン誘導新規複素環式化合物、その製造方法および薬剤としてのその利用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: MERRELL DOW PHARMACEUTICALS INC. |